8 141 antimicrobials used, and non-antimicrobial treatments was manually extracted from these records 142 by one investigator (AS). Isolates from submissions that explicitly stated no usage of 143 antimicrobial drugs were assigned the treatment history classification of none ("0"). Isolates 144 from cases in which information regarding antimicrobial treatments was unclear (e.g., "many" or 145 "everything") or not given were classified as "unknown." Isolates from cases with treatment 146 histories indicating the use of four or more antimicrobials were classified as "4+."
147
Trade names were converted to generic drug names to determine the antimicrobial drug 148 class (bacteriostatic or bactericidal) and the sequence of class administration for first-and 149 second-line treatments. Drug class was assigned based on the established in vitro 150 pharmacodynamics of the antimicrobial agent as summarized in Table 1 .
151 (Tables S1 and S2 ). Finalized case report information, such as 156 microscopic evidence of pneumonia, also was noted. Case information was classified as 157 "unknown" if the information was not supplied or unclear. After each eligible record was 158 identified, the submission forms for each case were individually reviewed by a single researcher 159 (AS). Antimicrobial treatments were grouped as -cidal or -static based on antimicrobial activity 160 level.
161 Variable transformations 162 Due to sparse data for cases receiving multiple treatments, we arbitrarily chose to group 163 together animals that received more than three treatments (4+). Animals with unknown treatment 164 histories were excluded from the analysis.
165
For the subset of animals receiving just two treatments, we created two categorical 166 variables. One categorical variable grouped the data into two levels: "same" to designate animals 167 that received first-and second-line treatment from the same drug class (i.e., either bacteriostatic 168 and bacteriostatic or bactericidal and bactericidal) and "different" to designate animals that 169 received first-and second-line treatment from different drug classes (i.e., either bacteriostatic 170 followed by bactericidal or bactericidal followed by bacteriostatic). We also created a four-level 171 categorical variable to capture all possible combinations (4 levels: bacteriostatic followed by 172 bactericidal, bacteriostatic followed by bacteriostatic, bactericidal followed by bacteriostatic, and 173 bactericidal followed by bactericidal). 
208
One output from each model was the posterior distribution of  i based on each i th level of 209 the explanatory variable; i.e.,  i is the probability that an animal in group i comes from the 210 binomial distribution. We use this posterior distribution to make inferences about the data. For 211 example, we are interested in the probability that an organism is resistant to at least one 212 antimicrobial, which is given by  i * (probability binomial [18,  i ] random variable > 0). We are 213 also interested in whether this probability is associated with either the number of times an animal 214 is treated or the treatment sequence. The other output was the posterior distribution of  i based on 215 each i th level of the explanatory variable. Posterior  distributions that are shifted to the right 216 indicate an isolate that is resistant to a higher number of antimicrobials.
217
To "test" the relationship between the probability of at least one resistant test result and 218 the number of treatments, we determined the posterior distribution of p i+1 > p i , i.e., how often the 219 probability of having at least one resistant test was higher for i + 1 treatments compared to i 220 treatments.
221
After creating the models, we assessed several discrepancy measures, including the 222 number of zeros in the posterior distribution of y* and the number of extreme values. This first 223 reflects the inflation of zeros in the observed distribution and is mainly informed by the posterior 224 distribution of  i. The second measure assesses the distribution of resistant organisms, given that 225 they are resistant, and is mainly informed by the posterior distribution of  i. For each posterior 226 distribution of  i and  i , we reported the 95% credible interval (95% CI) and also the posterior 227 probability that  i <  i and  i <  i. for all possible pairwise comparisons.
228 Ancillary analyses and sensitivity analyses 229 We originally intended to conduct further subgroup analysis based on the particular 230 isolates of M. haemolytica, P. multocida, and H. somni. However, on further examination, we 231 determined that the data were too sparse to warrant further subgrouping. We also were originally 232 interested in the impact of two covariates, simultaneous viral and Mycoplasma spp. infection, on 233 the posterior distribution; however, descriptive analysis indicated that this approach was unlikely 234 to be useful. Thus, although we extracted these data, we did not conduct these analyses. 
Results and Discussion

274
The observed antimicrobial susceptibility profiles for M. haemolytica based on MIC data 275 of cattle administered either the "same" (first and second treatment were both either bactericidal 276 drugs, or bacteriostatic drugs) or "different" (first treatment was bactericidal and second was 277 bacteriostatic or vice versa) antimicrobial treatment is presented in Fig. 1 . A similar examination 278 of the data was not conducted for P. multocida and H. somni because there were an insufficient 279 number of isolates for this to be meaningful. 
286
Antimicrobial treatments were grouped based on their anticipated impact on bacterial 287 growth in vitro, i.e., bactericidal ("cidal") or bacteriostatic ("static"). We created a heatmap to 288 illustrate the impact of specific pairs of combinations of first and second antimicrobial treatments 289 on the number of isolates identified as resistant against the listed antimicrobials with CLSI 290 breakpoints (Fig. 2) . Red indicates the observed maximum number of resistant isolates and white 291 (i.e., blank) represents no observation of antimicrobial resistance for a specific antimicrobial 292 combination (Fig. 2) . A similar examination of the data was not conducted for P. multocida and 293 H. somni because there were an insufficient number of isolates for this to be meaningful. 
304
Due to the limited number of isolates available from animals that received more than 2 305 treatments, we did not explore or conduct sensitivity analysis on the impact of other possible 306 antimicrobial combinations on the isolation of resistant organisms. We also did not explore 307 alternatives to the priors chosen for the Bayesian analysis, as we considered the chosen priors to 308 be the most biologically defensible. A variable to account for the non-independence of isolates 309 from the same animal was not included in the model, as the number of these cases was relatively 310 small.
311
The distribution of AMR in bacterial isolates demonstrated an association between the 312 isolation of an AMR bacteria and the number of treatments used ( Fig. 3 and Table 3 ). The data 313 indicate that administration of two or more antimicrobial agents to treat BRD in cattle may 314 increase the likelihood of isolating an antimicrobial resistant pathogen (Fig. 3) . 319 Table 3 . 95% credible intervals (95% CIs) for the posterior distributions representing the 320 probability of having at least one resistance result to at least one of the assessed 321 antimicrobials (i.e., ρ) based on CLSI breakpoints stratified by the number of 322 antimicrobials the animal received.
Objective, Model Percentile
Objective Table 5 ).
342 Fig. 5 . Posterior distributions of the probability that the isolate is resistant to multiple 343 antimicrobials (i.e.,  i ) stratified by treatment frequency. 0 = no treatment, 1 = 1 treatment, 344 2 = 2 treatments, 3 = 3 treatments, and 4+ = 4 or more treatments.
345 
357
Objective 2 examined the development of resistance based on whether the antimicrobial 358 selected for the initial treatment and retreatment would be expected to kill the bacteria in-vitro 382 Model 2 explores whether the sequence of bactericidal and bacteriostatic treatments has an 383 impact on the probability of recovering a resistant BRD isolate. This analysis suggests that there 384 is little impact of the treatment scheme sequence on the probability of identifying an isolate that 385 is resistant to at least one antimicrobial (ρ). The specific posterior distributions and the 95% CI 386 of ρ are shown in Error! Reference source not found.. 8 and Error! Reference source not 387 found. 3. Similarly, the posterior probability of an organism being resistant to at least one 388 antimicrobial is presented in Table 7 . 395 Table 7 . Posterior probability that p i+1 is greater than p i (i -4-level treatment mechanism 396 sequence for objective 2 model 2). 398 As reported in Table 7 , the probability of an organism being resistant to at least one antibiotic 399 (ρ) was similar for the different treatment combinations. Specifically, in 62%, 81%, and 35% of 400 cases, the probability of an organism being resistant to at least one antibiotic was higher if 401 animals received a bacteriostatic antimicrobial for first treatment followed by a bactericidal 402 antimicrobial for retreatment of BRD when compared to bacteriostatic-bacteriostatic, 403 bactericidal-bacteriostatic, and bactericidal-bactericidal treatment, respectively.
Bactericidal
404
With respect to the treatment, posterior gamma (γ) distributions shifted to the right in 405 animals that received a first line, bacteriostatic antimicrobials followed by retreatment with a 406 bactericidal antimicrobial (Error! Reference source not found.. 9). This suggests that BRD 407 pathogens isolated from these animals would be more likely to test resistant to more than one 408 antimicrobial (Table 5 ). The probability of obtaining a resistant isolate from an animal receiving 409 first-line bacteriostatic treatment followed by retreatment with a bactericidal antimicrobial being 410 higher than the other sequences was >95% (Error! Reference source not found. 8).
411 Table 8 . Posterior probability that the γ i is greater γ i-1 (i -4-level treatment mechanism 412 sequence for objective 2 model 2) where  i = number of resistant tests for an isolate. 
428
To our knowledge, this survey is the first report that specifically considers AMR in 429 livestock in the context of retreatments by different classes of antimicrobials (i.e., bacteriostatic 430 and bactericidal) as well as different individual drugs (i.e., tulathromycin versus enrofloxacin).
431 As such, this report provides insights into potential critical control points for antimicrobial 432 stewardship in livestock production systems. For example, the heat map (Fig. 2) 455 haemolytica and P. multocida is the long elimination half-life of macrolides results in prolonged 525 including comprehensive treatment histories to accompany the submission of veterinary 526 diagnostic laboratory samples. The current study of antimicrobial sensitivity patterns in a region 527 can guide veterinarians to choose safer and more effective treatment protocols. Future studies on 528 antimicrobial resistance could facilitate decision-making when animals contained in feedlots 529 exhibit chronic illness and there is the potential need for multiple treatments with antimicrobial 530 agents.
531
Key results
532
These exploratory data suggest that treatment protocols stipulating first-line treatment 533 with a bacteriostatic followed by second-line treatment with a bactericidal may increase the 534 probability that drug resistance develops. As concern about antimicrobial resistance increases 535 from an animal and public health perspective, this knowledge suggests potential ways to reduce 536 the development of resistance. The hypothesis that the impact of an antimicrobial on bacterial 537 growth may be associated with the risk of increased resistance needs to be tested in a clinical 538 trial. Such a trial would also need to determine whether treatment efficacy is affected by a 539 change in treatment protocol or post-treatment interval. If treatment effectiveness proves to be 540 the same, then we may have an avenue by which to reduce the induction of resistance via the 541 recommendation that veterinarians tailor their treatment regimens to reduce the potential for 542 AMR development.
543
Strengths and limitations 544
Although this study is hypothesis-generating, it has several strengths. The data set is 545 reasonably large for the questions we asked. Although a great deal of data were missing, we 546 limited our analysis to specific questions to avoid impact due to this missing data. Furthermore, 547 we recognized the limits of the passively collected and hypothesis-generating nature of the data
